Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • ODD

    - PMLiVE

    Novartis gains rights to PTC’s Huntington’s programme in deal worth up to $2.9bn

    The genetic disorder affects one in every 10,000 to 20,000 people in the US

    - PMLiVE

    uniQure’s investigational gene therapy shown to slow Huntington’s disease progression

    The neurodegenerative disorder affects approximately 70,000 people in Europe and the US

    - PMLiVE

    Novartis and Voyager enter gene therapy partnership worth over $1.2bn

    The companies will advance candidates for Huntington’s disease and spinal muscular atrophy

    - PMLiVE

    Novartis to temporarily suspend Huntington’s disease phase 2b study after side effects reported

    A data review found that branaplam may cause peripheral neuropathy, which is the result of nerve injury outside the brain and spinal cord

    - PMLiVE

    FDA removes clinical hold on uniQure’s haemophilia gene therapy

    Clinical hold placed following a case of hepatocellular carcinoma in a patient in the trial

    - PMLiVE

    New results back Sangamo, UniQure haemophilia gene therapies

    Encouraging results for firms in four-way race

    - PMLiVE

    UniQure gets speedy US review for Huntington’s gene therapy

    Pioneer gaining momentum again

    - PMLiVE

    UniQure edges closer to haemophilia B gene therapy OK

    The candidate could free patients from regulator injections of FIX products

    - PMLiVE

    UniQure cleared to start Huntington gene therapy trial

    AMT-130 becomes the first AAV-based therapy approved for trials in Huntington’s disease

    - PMLiVE

    UniQure skyrockets on haemophilia B gene therapy data

    Competition with Pfizer and Spark rival heats up

    - PMLiVE

    UniQure’s starts pivotal haemophilia B gene therapy trial

    The treatment could relieve haemophilia B patients from factor IX replacement drugs

    - PMLiVE

    EMA hands UniQure orphan status first in Huntington’s

    The Dutch biotech expects to file the treatment for approval later this year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links